Micromechanical finite element modelling of thermo-mechanical fatigue for P91 steels

In this paper, the cyclic plasticity and fatigue crack initiation behaviour of a tempered martensite ferritic steel under thermo-mechanical fatigue conditions is examined by means of micromechanical finite element modelling. The crystal plasticity-based model explicitly reflects the microstructure of the material, measured by electronic backscatter diffraction. The predicted cyclic thermo-mechanical response agrees well with experiments under both in-phase and out-of-phase conditions. A thermo-mechanical fatigue indicator parameter, with stress triaxiality and temperature taken into account, is developed to predict fatigue crack initiation. In the fatigue crack initiation simulation, the out-of-phase thermo-mechanical response is identified to be more dangerous than in-phase response, which is consistent with experimental failure data. It is shown that the behaviour of thermo-mechanical fatigue can be effectively predicted at the microstructural level and this can lead to a more accurate assessment procedure for power plant components

1966

Proper Watering by Earl P. Grey (page 1) Soil Structure and Plant Feeding for Trees and Shrubs on the Golf Course by William Teece (2) Power Golf Carts: A Blessing or a Curse by David Dunlavey (3) A Comparison by Paul White (3) Trees on a Golf Course by Oliver Leech (5) Turf Management Majors Want a Golf Team by Richard Rossiter (6) Class Will of \u2766 (7)Famous Last Words from 1966 (8) Turf Heating with Electric Cables by J.R. Barrett, Jr. and W.H. Daniel (A-1) Poa Annua Restriction by C. F. Kerr and W.H. Daniel (A-9) Phosphorus by Marvin H. Ferguson (A-14) Role of Potassium in Turf Grass management by R. E. Wagner (A-16) Role of Minor Elements in Turfgrass Management by Alexander Radko (A-22) Rhizoctonia Brown patch and Pythium Diseas by Malcolm C. Shurtleff (A-27) Sclerotinia Dollar Spot and Snow Mold by Noel Jackson (A-32) Fusarium Blight - Disease of Turf Grasses by George A. Bean (A-35) Observing the Weather - Old and New Techniques by Robert C. Copeland (A-39) Water Supply by Allan Grieve Jr. (A-41) Establishment and Maintenance of Campus Turf by William A. Lambert (A-51) Athletic Field Management by J. T. Williams (A-56

H5N1 Whole-Virus Vaccine Induces Neutralizing Antibodies in Humans Which Are Protective in a Mouse Passive Transfer Model

BACKGROUND: Vero cell culture-derived whole-virus H5N1 vaccines have been extensively tested in clinical trials and consistently demonstrated to be safe and immunogenic; however, clinical efficacy is difficult to evaluate in the absence of wide-spread human disease. A lethal mouse model has been utilized which allows investigation of the protective efficacy of active vaccination or passive transfer of vaccine induced sera following lethal H5N1 challenge. METHODS: We used passive transfer of immune sera to investigate antibody-mediated protection elicited by a Vero cell-derived, non-adjuvanted inactivated whole-virus H5N1 vaccine. Mice were injected intravenously with H5N1 vaccine-induced rodent or human immune sera and subsequently challenged with a lethal dose of wild-type H5N1 virus. RESULTS: Passive transfer of H5N1 vaccine-induced mouse, guinea pig and human immune sera provided dose-dependent protection of recipient mice against lethal challenge with wild-type H5N1 virus. Protective dose fifty values for serum H5N1 neutralizing antibody titers were calculated to be ≤1∶11 for all immune sera, independently of source species. CONCLUSIONS: These data underpin the confidence that the Vero cell culture-derived, whole-virus H5N1 vaccine will be effective in a pandemic situation and support the use of neutralizing serum antibody titers as a correlate of protection for H5N1 vaccines

A multi-scale crystal plasticity model for cyclic plasticity and low-cycle fatigue in a precipitate-strengthened steel at elevated temperature

peer-reviewedIn this paper, a multi-scale crystal plasticity model is presented for cyclic plasticity and low-cycle fatigue in a tempered martensite ferritic steel at elevated temperature. The model explicitly represents the geometry of grains, sub-grains and precipitates in the material, with strain gradient effects and kinematic hardening included in the crystal plasticity formulation. With the multiscale model, the cyclic behaviour at the sub-grain level is predicted with the effect of lath and precipitate sizes examined. A crystallographic, accumulated slip (strain) parameter, modulated by triaxiality, is implemented at the micro scale, to predict crack initiation in precipitate-strengthened laths. The predicted numbers of cycles to crack initiation agree well with experimental data. A strong dependence on the precipitate size is demonstrated, indicating a detrimental effect of coarsening of precipitates on fatigue at elevated temperature. (C) 2016 Elsevier Ltd. All rights reserved.ACCEPTEDpeer-reviewe

A Pandemic Influenza H1N1 Live Vaccine Based on Modified Vaccinia Ankara Is Highly Immunogenic and Protects Mice in Active and Passive Immunizations

The development of novel influenza vaccines inducing a broad immune response is an important objective. The aim of this study was to evaluate live vaccines which induce both strong humoral and cell-mediated immune responses against the novel human pandemic H1N1 influenza virus, and to show protection in a lethal animal challenge model.For this purpose, the hemagglutinin (HA) and neuraminidase (NA) genes of the influenza A/California/07/2009 (H1N1) strain (CA/07) were inserted into the replication-deficient modified vaccinia Ankara (MVA) virus - a safe poxviral live vector – resulting in MVA-H1-Ca and MVA-N1-Ca vectors. These live vaccines, together with an inactivated whole virus vaccine, were assessed in a lung infection model using immune competent Balb/c mice, and in a lethal challenge model using severe combined immunodeficient (SCID) mice after passive serum transfer from immunized mice. Balb/c mice vaccinated with the MVA-H1-Ca virus or the inactivated vaccine were fully protected from lung infection after challenge with the influenza H1N1 wild-type strain, while the neuraminidase virus MVA-N1-Ca induced only partial protection. The live vaccines were already protective after a single dose and induced substantial amounts of neutralizing antibodies and of interferon-γ-secreting (IFN-γ) CD4- and CD8 T-cells in lungs and spleens. In the lungs, a rapid increase of HA-specific CD4- and CD8 T cells was observed in vaccinated mice shortly after challenge with influenza swine flu virus, which probably contributes to the strong inhibition of pulmonary viral replication observed. In addition, passive transfer of antisera raised in MVA-H1-Ca vaccinated immune-competent mice protected SCID mice from lethal challenge with the CA/07 wild-type virus.The non-replicating MVA-based H1N1 live vaccines induce a broad protective immune response and are promising vaccine candidates for pandemic influenza

A Whole Virus Pandemic Influenza H1N1 Vaccine Is Highly Immunogenic and Protective in Active Immunization and Passive Protection Mouse Models

The recent emergence and rapid spread of a novel swine-derived H1N1 influenza virus has resulted in the first influenza pandemic of this century. Monovalent vaccines have undergone preclinical and clinical development prior to initiation of mass immunization campaigns. We have carried out a series of immunogenicity and protection studies following active immunization of mice, which indicate that a whole virus, nonadjuvanted vaccine is immunogenic at low doses and protects against live virus challenge. The immunogenicity in this model was comparable to that of a whole virus H5N1 vaccine, which had previously been demonstrated to induce high levels of seroprotection in clinical studies. The efficacy of the H1N1 pandemic vaccine in protecting against live virus challenge was also seen to be equivalent to that of the H5N1 vaccine. The protective efficacy of the H1N1 vaccine was also confirmed using a severe combined immunodeficient (SCID) mouse model. It was demonstrated that mouse and guinea pig immune sera elicited following active H1N1 vaccination resulted in 100% protection of SCID mice following passive transfer of immune sera and lethal challenge. The immune responses to a whole virus pandemic H1N1 and a split seasonal H1N1 vaccine were also compared in this study. It was demonstrated that the whole virus vaccine induced a balanced Th-1 and Th-2 response in mice, whereas the split vaccine induced mainly a Th-2 response and only minimal levels of Th-1 responses. These data supported the initiation of clinical studies with the same low doses of whole virus vaccine that had previously been demonstrated to be immunogenic in clinical studies with a whole virus H5N1 vaccine

Vectors Based on Modified Vaccinia Ankara Expressing Influenza H5N1 Hemagglutinin Induce Substantial Cross-Clade Protective Immunity

New highly pathogenic H5N1 influenza viruses are continuing to evolve with a potential threat for an influenza pandemic. So far, the H5N1 influenza viruses have not widely circulated in humans and therefore constitute a high risk for the non immune population. The aim of this study was to evaluate the cross-protective potential of the hemagglutinins of five H5N1 strains of divergent clades using a live attenuated modified vaccinia Ankara (MVA) vector vaccine.The replication-deficient MVA virus was used to express influenza hemagglutinin (HA) proteins. Specifically, recombinant MVA viruses expressing the HA genes of the clade 1 virus A/Vietnam/1203/2004 (VN/1203), the clade 2.1.3 virus A/Indonesia/5/2005 (IN5/05), the clade 2.2 viruses A/turkey/Turkey/1/2005 (TT01/05) and A/chicken/Egypt/3/2006 (CE/06), and the clade 2.3.4 virus A/Anhui/1/2005 (AH1/05) were constructed. These experimental live vaccines were assessed in a lethal mouse model. Mice vaccinated with the VN/1203 hemagglutinin-expressing MVA induced excellent protection against all the above mentioned clades. Also mice vaccinated with the IN5/05 HA expressing MVA induced substantial protection against homologous and heterologous AH1/05 challenge. After vaccination with the CE/06 HA expressing MVA, mice were fully protected against clade 2.2 challenge and partially protected against challenge of other clades. Mice vaccinated with AH1/05 HA expressing MVA vectors were only partially protected against homologous and heterologous challenge. The live vaccines induced substantial amounts of neutralizing antibodies, mainly directed against the homologous challenge virus, and high levels of HA-specific IFN-γ secreting CD4 and CD8 T-cells against epitopes conserved among the H5 clades and subclades.The highest level of cross-protection was induced by the HA derived from the VN/1203 strain, suggesting that pandemic H5 vaccines utilizing MVA vector technology, should be based on the VN/1203 hemagglutinin. Furthermore, the recombinant MVA-HA-VN, as characterized in the present study, would be a promising candidate for such a vaccine